GB-115
Also known as: Ranquilon, N-phenylacetyl-L-prolylglycine ethyl ester
A dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia and currently in clinical trials for anxiety and cognitive enhancement. Users report significant improvements in focus, attention, and ADHD-like symptoms.
Mechanism of Action
GB-115 works by blocking central cholecystokinin-1 (CCK-1) receptors in the brain. CCK is involved in anxiety, panic responses, and cognitive modulation. By antagonizing these receptors, GB-115 reduces anxiety while improving attention, processing speed, and reaction time. It also modulates dopaminergic pathways involved in focus and motivation.
Research Summary
Clinical studies in patients with Generalized Anxiety Disorder (GAD) showed GB-115 (6mg/day) significantly improved reaction time, attention, and processing speed within 7 days of treatment. A 21-day trial with 31 patients demonstrated anxiolytic effects comparable to benzodiazepines without sedation or dependency. Currently in Phase II/III trials (NCT05586789) for anxiety disorders. Anecdotal reports suggest benefits for ADHD symptoms, though direct ADHD trials are pending.
Research Protocols
Note: Doses observed in research studies
Common Doses
Duration
21+ days in clinical trials, effects noted by day 7
Administration
Oral tablets or sublingual
Timing & Administration
CognitiveAs a Cognitive peptide: Morning and throughout the day is the recommended administration time.
Best Time to Take
Morning and throughout the day
2-3 times daily for consistent effects
Food Recommendation
either
Why This Timing?
Based on mechanism of action: Clinical trials used three times daily dosing (morning, afternoon, evening) for consistent receptor occupancy. Can be taken with or without food.
Timing recommendations are based on pharmacological principles and mechanism of action, not dedicated clinical trials on administration timing. Most peptide studies focus on efficacy rather than optimal timing. Consult a healthcare provider for personalized guidance.
Side Effects & Considerations
- ●Generally well-tolerated
- ●Minimal sedation compared to benzodiazepines
- ●Headache (rare)
- ●Mild gastrointestinal discomfort
- ●No reported dependency or withdrawal
- ●Limited long-term safety data
- ●Not FDA approved
References
Want updates on GB-115 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.